Cardiovascular disease and stroke are major causes of morbidity and mortality. Although many pathophysiological processes play a role in the development of vascular disease, thrombosis often is the event that precipitates stroke and acute coronary syndromes. Many platelet receptors and activation pathways are conserved in other cell types, including neurons. Platelets release the neurotransmitter glutamate during activation, but the role of glutamate signaling in the vasculature is unknown. We have discovered that platelets express ionotropic glutamate receptors, including the AMPA type receptor (AMPAR) and the Kainic Acid (KA) type receptor (KAR). Furthermore, we demonstrate that AMPA and KA receptor signaling increase platelet activation. We hypothesize that platelets express functional glutamate sensitive complexes that increase agonist induced platelet activation and thrombosis. To explore this hypothesis, we propose the following Specific Aims:
Specific Aim 1 : To define the mechanisms of glutamate mediated increase in agonist induced platelet activation. We will extend our extensive Preliminary Data to further explore the regulation of platelet activation by ionotropic glutamate receptors. Using flow cytometry, platelet aggregation, and whole cell patch clamp techniques we will further dissect platelet glutamate signaling.
Specific Aim 2 : To define platelet glutamate receptor accessory molecule interactions.
Aim 2 will focus on the molecular machinery that facilitates AMPAR and KAR membrane localization and stability in platelets.
Specific Aim 3 : To demonstrate that glutamate signaling promotes thrombosis and ischemia-reperfusion injury. To further explore glutamate regulation of platelet function we will use in vivo measurements of platelet function, including bleeding time and thrombosis. We will also demonstrate the importance of the promotion of platelet activation by AMPAR and KAR using a model of ischemia- reperfusion injury.
In 2001, a World Health Report noted atherothrombosis (ischemic heart disease and stroke) to be the leading cause of death worldwide. Platelets have a prominent role in cardiovascular disease and platelet inhibitors are a main therapeutic intervention. The proposed study will help elucidate novel targets for the development of new therapies in the prevention and treatment of cardiovascular disease.
|Heo, Kyung-Sun; Chang, Eugene; Takei, Yuichiro et al. (2013) Phosphorylation of protein inhibitor of activated STAT1 (PIAS1) by MAPK-activated protein kinase-2 inhibits endothelial inflammation via increasing both PIAS1 transrepression and SUMO E3 ligase activity. Arterioscler Thromb Vasc Biol 33:321-9|
|Shi, Guanfang; Field, David J; Long, Xiaochun et al. (2013) Platelet factor 4 mediates vascular smooth muscle cell injury responses. Blood 121:4417-27|
|Aggrey, Angela A; Srivastava, Kalyan; Ture, Sara et al. (2013) Platelet induction of the acute-phase response is protective in murine experimental cerebral malaria. J Immunol 190:4685-91|
|Shi, Guanfang; Morrell, Craig N (2011) Platelets as initiators and mediators of inflammation at the vessel wall. Thromb Res 127:387-90|
|Morrell, Craig N; Maggirwar, Sanjay B (2011) Recently recognized platelet agonists. Curr Opin Hematol 18:309-14|
|Davidson, Donna C; Hirschman, Michael P; Spinelli, Sherry L et al. (2011) Antiplatelet activity of valproic acid contributes to decreased soluble CD40 ligand production in HIV type 1-infected individuals. J Immunol 186:584-91|
|Swaim, AnneMarie F; Field, David J; Fox-Talbot, Karen et al. (2010) Platelets contribute to allograft rejection through glutamate receptor signaling. J Immunol 185:6999-7006|
|Ombrello, Christopher; Block, Robert C; Morrell, Craig N (2010) Our expanding view of platelet functions and its clinical implications. J Cardiovasc Transl Res 3:538-46|
|Srivastava, Kalyan; Field, David J; Aggrey, Angela et al. (2010) Platelet factor 4 regulation of monocyte KLF4 in experimental cerebral malaria. PLoS One 5:e10413|
|Wehner, Jennifer R; Morrell, Craig N; Rodriguez, E Rene et al. (2009) Immunological challenges of cardiac transplantation: the need for better animal models to answer current clinical questions. J Clin Immunol 29:722-9|